02:26:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-11-15 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-12 Kvartalsrapport 2022-Q2
2022-05-13 Ordinarie utdelning GENO 0.00 SEK
2022-05-12 Årsstämma 2023
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-08 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning GENO 0.00 SEK
2021-05-20 Årsstämma 2021
2021-04-29 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-06 Ordinarie utdelning GENO 0.00 SEK
2020-05-05 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-05 Bokslutskommuniké 2019
2019-12-20 Extra Bolagsstämma 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning GENO 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-26 Bokslutskommuniké 2018
2018-11-27 Kvartalsrapport 2018-Q3
2018-08-28 Kvartalsrapport 2018-Q2
2018-05-18 Ordinarie utdelning GENO 0.00 SEK
2018-05-17 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-27 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning GENO 0.00 SEK
2017-05-11 Årsstämma 2017
2017-05-08 Kvartalsrapport 2017-Q1
2017-02-27 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-08-29 Kvartalsrapport 2016-Q2
2016-05-12 Årsstämma 2016
2016-05-06 Ordinarie utdelning GENO 0.00 SEK
2016-05-04 Kvartalsrapport 2016-Q1
2016-02-15 Bokslutskommuniké 2015
2015-11-23 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-11 Kvartalsrapport 2015-Q1
2015-05-06 Ordinarie utdelning GENO 0.00 SEK
2015-05-05 Årsstämma 2015
2015-02-18 Bokslutskommuniké 2014
2014-11-17 Kvartalsrapport 2014-Q3
2014-08-25 Kvartalsrapport 2014-Q2
2014-05-21 Ordinarie utdelning GENO 0.00 SEK
2014-05-20 Årsstämma 2014
2014-05-19 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-04-26 Ordinarie utdelning GENO 0.00 SEK
2013-04-25 Årsstämma 2013
2013-04-24 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-14 Kvartalsrapport 2012-Q3
2012-08-29 Kvartalsrapport 2012-Q2
2012-04-25 Kvartalsrapport 2012-Q1
2012-04-04 Split GENO 10:1
2012-03-21 Ordinarie utdelning GENO 0.00 SEK
2012-03-20 Årsstämma 2012
2012-02-16 Bokslutskommuniké 2011
2011-11-10 Kvartalsrapport 2011-Q3
2011-08-26 Kvartalsrapport 2011-Q2
2011-07-21 Extra Bolagsstämma 2011
2011-06-09 Årsstämma 2011
2011-04-29 Ordinarie utdelning GENO 0.00 SEK
2011-04-18 Kvartalsrapport 2011-Q1
2011-02-15 Bokslutskommuniké 2010
2010-11-05 Kvartalsrapport 2010-Q3
2010-08-20 Kvartalsrapport 2010-Q2
2010-05-18 Kvartalsrapport 2010-Q1
2010-03-31 Ordinarie utdelning GENO 0.00 SEK
2010-03-30 Årsstämma 2010
2010-02-26 Bokslutskommuniké 2009
2009-11-12 Kvartalsrapport 2009-Q2
2009-10-08 Kvartalsrapport 2009-Q3
2009-06-03 Ordinarie utdelning GENO 0.00 SEK
2009-06-02 Årsstämma 1
2009-04-21 Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Genovis är verksamma inom bioteknik. Störst inriktning inom verksamheten återfinns mot utveckling av enzymer som används i diverse läkemedel. Bolagets patenterade NIMT teknologi är utvecklad för att underlätta för LifeScience industrin att bedriva preklinisk forskning. Bolagets produkter vidaresäljs under ett flertal varumärken. Genovis etablerades 1999 och har sitt huvudkontor i Lund.
2022-11-15 08:00:00
July - September 2022
  • Net sales totaled SEK 22,979 (15,699) thousand, with a growth rate of 46%. Growth is 26%, adjusted for currency effects.
  • Gross profit rose by 58% to SEK 22,475 (14,195) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 6,997 (2,202) thousand.
  • Operating profit jumped SEK 4,246 thousand and totaled SEK 4,993 (747) thousand.
  • Comprehensive income for the period totaled SEK 5,869 (1,013) thousand.
  • Comprehensive income per share totaled SEK 0.09 (0.02).
  • Cash flow from operating activities was SEK 5,042 (4,613) thousand.
  • Cash and cash equivalents at the end of the period totaled SEK 80,987 (45,210) thousand.
January - September 2022
  • Net sales totaled SEK 76,646 (50,957) thousand, with a growth rate of 50%. Growth is 34%, adjusted for currency effects.
  • Gross profit rose by 59% to SEK 74,049 (46,577) thousand.
  • Operating profit before depreciation and amortization (EBITDA) totaled SEK 20,824 (6,954) thousand.
  • Operating profit jumped SEK 12,671 thousand and totaled SEK 15,320 (2,649) thousand.
  • Comprehensive income for the period totaled SEK 19,766 (3,653) thousand.
  • Comprehensive income per share totaled SEK 0.30 (0.06).
  • Cash flow from operating activities was SEK 3,605 (6,377) thousand.

Comments from Fredrik Olsson, Chief Executive Officer

Sales increased by about 46% in the third quarter, 26% adjusted for currency effects, and we achieved an operating profit of approximately SEK 5 million. 

We note that the influence of the coronavirus pandemic is gradually easing, which has had a positive impact on our customers' activity. They are returning to a greater extent to the laboratories and projects that are less focused on vaccines and Covid-19-related drug projects.

Sales of enzymes increased by about 44% and we saw growth in all geographic markets, with Asia and North America making the strongest contributions during the quarter. Revenue from gene therapy and bioprocess is expected to contribute to volatility in individual quarters in the short term and in third quarter bioprocess contributed with SEK 1.5 million. The antibody business also saw a strong performance during the quarter, with growth of about 60%. The recently launched service business for antibody analysis have been initiated and first orders have been delivered in the quarter. Overall, our sales performed well and the expansion of our commercial organization, combined with a broader product offering, is reflected in increased customer interaction and new customers.

Our total cost base has increased compared with the corresponding period last year. The increase in the cost of raw materials is largely associated with price increases that have been further accelerated by currency effects, since many of the raw materials are directly linked to other currencies. We have periodically experienced certain supply chain challenges and we are actively working with our suppliers to secure access to raw materials. Personnel costs have increased as a result of the strategic growth initiatives in our commercial organization and associated currency effects.

At the end of the second quarter we launched two new products, GlySERIAS and OmniGLYZOR. Both products have been well received, but GlySERIAS has initially generated tangible commitment among our customers. GlySERIAS mainly focuses on new formats of biopharmaceuticals, outside traditional antibodies, and the customer response has exceeded expectations.

In September, we carried out additional key hires to our commercial organization, in line with the planned strategies for the year. The new members of the commercial organization have been well integrated into our team during the year, thanks to excellent help and support from other parts of the organization, which contributed strongly to the successful initiative.

As yet, we have not experienced any clear impact among our customers due to the geopolitical and macroeconomic situation and the beginning of the fourth quarter has shown continued good customer activity in our various markets.

I would like to conclude by extending a warm thank you to my colleagues at Genovis who do amazing work for our customers every day in their quest to develop new and better treatments for patients around the world.

This disclosure contains information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-11-2022 08:00 CET.